Spots Global Cancer Trial Database for aeg35156
Every month we try and update this database with for aeg35156 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | NCT00372736 | Unspecified Adu... | AEG35156 docetaxel protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Study of XIAP Antisense for Advanced Cancers | NCT00385775 | Advanced Cancer | AEG35156 | 18 Years - | Aegera Therapeutics | |
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | NCT01018069 | Leukemia | AEG35156 | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | NCT00372736 | Unspecified Adu... | AEG35156 docetaxel protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer | NCT00558545 | Human Mammary C... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| AEG35156 and Docetaxel in Treating Patients With Solid Tumors | NCT00357747 | Unspecified Adu... | AEG35156 docetaxel | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Study of XIAP Antisense for Advanced Cancers | NCT00385775 | Advanced Cancer | AEG35156 | 18 Years - | Aegera Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
